Oxytetracycline Hcl/base, Doxycycline Hcl, Gliclazide Bp2004, Trimethoprim, Smz, Omeprazole Pellets Etc.
New Products From This Supplier
We are known for manufacturing the best in the international market value wise. We are rolling out in international market with cheap prices for and oxytetracycline hcl/base, doxycycline hcl, gliclazide bp2004, trimethoprim, smz, omeprazole pellets etc. products produced in china. Our company can provide high quality cardiovascular drugs & medication and various other china oxytetracycline hcl/base, doxycycline hcl, gliclazide bp2004, trimethoprim, smz, omeprazole pellets etc. products, as they are a famous manufacturer. Our company is a topmost enterprise in china that is trading globally.
Business Nature
Manufacturer
No. Employees
Fewer than 5
Year Established
2011
Annual Turnover
More than 6 Million US Dollar
Country/Region
Shanghai, China
Main Products
Oxytetracycline Hcl/base...
Legal Status
Agency
Payment Terms
Bank wire (T/T), Letter of Credit (L/C), Doc Against Acceptance (D/A), Credit Card (CC)
SUAN PHARMA CO LIMITED is one of the top Manufacturer supplying Medical & Healthcare and many more China Oxytetracycline Hcl/base, Doxycycline hcl, Gliclazide BP2004, Trimethoprim, SMZ, Omeprazole pellets etc. goods. The warehouse of SUAN PHARMA CO LIMITED is located in shanghai Shanghai China. SUAN PHARMA CO LIMITED is a renowned company in China that is dealing in large scale market. SUAN PHARMA CO LIMITED Particulars Name: suqin xu
Address: shanghai Shanghai
Country: China
Main Products: Oxytetracycline Hcl/base, Doxycycline hcl, Gliclazide BP2004, Trimethoprim, SMZ, Omeprazole pellets etc.
Year Established: 2011
Export Focus: Australia, Brazil, Canada, South Korea, United Kingdom
Estimated Employees: 201 - 300 People
Registered Capital: US$10 Million - US$50 Million
Ownership Status: LLC (Limited Liability Corp)
Export Percentage: 41% - 50%
Factory Size: Above 100, 000 square meters
Production Lines: 3
Research Team Size: 11 - 50 People
Contract Services: Design Service Offered
